- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Year 2019
The Center for Biosimilars® recaps the top stories for the year 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the year 2019.
Number 5: In January, Pfizer confirmed that it made the decision to terminate 5 preclinical biosimilar programs after the results of the company’s annual investment review.
Number 4: Also in January, the FDA approved Samsung Bioepis’ Ontruzant, a biosimilar trastuzumab referencing Herceptin.
Number 3: In August, UnitedHealthcare indicated that it would prefer 2 oncology biosimilars in its commercial and community plans.
Number 2: In May, the FDA released its long-awaited final guidance on demonstrating interchangeability of a biosimilar with its reference.
Number 1: Finally, the US market got its first anticancer biosimilars in July when Amgen and Allergan launched biosimilar bevacizumab and trastuzumab.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
